0.3471

1.06% -0.0019

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $0.3471, with a volume of 1.29M. It is down -1.06% in the last 24 hours and down -20.24% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Previous Close:

$0.349

Open:

$0.34

24h Volume:

1.29M

Relative Volume:

0.45

Market Cap:

$43.36M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-0.2314

EPS:

-1.5

Net Cash Flow:

$-171.05M

1W Performance:

-1.99%

1M Performance:

-20.24%

6M Performance:

-84.86%

1Y Performance:

-85.61%

1-Day Range:

$0.3306

$0.3599

1-Week Range:

$0.3306

$0.381

52-Week Range:

$0.2589

$2.83

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

102

Twitter

@MersanaADC

Next Earnings Date

2025-03-03

Latest SEC Filings

MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRSN Mersana Therapeutics Inc	0.3479	48.61M	36.86M	-171.67M	-171.05M	-1.50
ONC Beone Medicines Ltd Adr	245.81	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.54	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.22	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	493.66	64.44B	14.09B	4.50B	2.96B	39.28

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-25	Initiated	William Blair	Outperform
Nov-15-24	Resumed	Citigroup	Buy
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

May 27, 2025

Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada

May 27, 2025

May 26, 2025

Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 26, 2025

May 25, 2025

D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 25, 2025

BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 25, 2025

May 22, 2025

Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace

May 22, 2025

May 21, 2025

Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister

May 21, 2025

May 20, 2025

Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus

May 20, 2025

Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan

May 20, 2025

Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 20, 2025

May 19, 2025

Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 19, 2025

William Blair Analysts Lift Earnings Estimates for MRSN - Defense World

May 19, 2025

Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World

May 19, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World

May 19, 2025

May 18, 2025

Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World

May 18, 2025

May 17, 2025

Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN

May 17, 2025

Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World

May 17, 2025